Drug intelligence / Profile preview

JUV-112

Development stage: Preclinical
Lead developer: Juvena Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

JUV-112 is a preclinical, protein-based therapeutic candidate developed by Juvena Therapeutics for the treatment of obesity and metabolic diseases. It is a secreted protein drug discovered using Juvena’s AI-enabled platform, designed to induce energy expenditure and promote lipolysis (fat breakdown) without suppressing appetite or causing muscle loss. The mechanism of action is distinct from incretin-based therapies and aims to enhance lipid metabolism through an orthogonal pathway. As of June 2025, JUV-112 remains in preclinical development with no clinical trials initiated yet[1][2][5][6][8][9].

Beyond the preview

Go deeper on JUV-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JUV-112.

Explore the full profile